B-cell therapy for stubborn IgG4-related disease
Part of Immune system & allergy clinical trials.
This trial tests a new treatment called BCT301 for people with IgG4-related disease (an autoimmune condition causing swelling in organs like the pancreas or kidneys) that has not improved with standard treatments. The therapy targets certain immune cells to help reduce disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and weigh at least 40 kg.
- You have been diagnosed with IgG4-related disease affecting organs like the pancreas, kidneys, lungs, or heart.
- Your disease is active or has come back despite standard treatments like steroids or immunosuppressants.
- You are currently on a stable dose of your treatments, and if you take steroids, the dose is 30 mg or less per day.
- Your blood counts and organ functions (like liver, kidney, heart) are within acceptable levels.
- You have not had certain prior treatments like CAR-T cell therapy, unless they clearly failed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
This study tests a new type of cell therapy (CAR-NK) that uses your own immune cells to target and attack the cells causing your IgG4-related disease. It may help people whose disease has not improved with standard treatments.
This study tests an investigational drug, ACE1831, in people with active IgG4-related disease (IgG4-RD), a condition where the immune system causes inflammation and swelling in organs. The purpose is to see if ACE1831 is safe and effective in reducing disease flare-ups, possibly offering a new treatment option.
This trial is testing a new investigational drug called IMM0306 for people with IgG4-related disease, a condition where the body's immune system attacks its own organs. If you're currently needing steroids for a flare, this study might offer a new treatment option that could help control the disease with fewer side effects.
This is a study that follows people diagnosed with IgG4-related disease to better understand the condition. It may help researchers confirm diagnoses and learn how the disease affects different organs over time.
This trial tests a drug called sirolimus (which helps calm the immune system) for people with active IgG4-related disease. It may help reduce symptoms like swelling and pain if your current treatments are not working well.
Hear when a new IgG4-Related Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.